Novel class of proteasome inhibitor may provide benefit in cancer treatment
Researchers at the California Institute of Technology (Pasadena, CA, USA) have suggested that a new class of proteasome inhibitor that targets the 19S subunit may be beneficial in overcoming cancer cell resistance to traditional proteasome inhibitors.
Please sign in or register for FREE
Sign in to RxNet
Register to RxNet
RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.